US stocks rose on Friday, May 2, as the S&P 500, Dow Jones Industrial Average, and the tech-heavy Nasdaq all posted ...

WisdomTree US High Dividend ETF (DHS) focuses on high-yield, quality U.S. equities, favoring defensive sectors. Read an ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Summit, a specialist in oncology, has made excellent clinical progress with its leading candidate, ivonescimab. There's more where that came from, too; Ivonescimab just knocked it out of the park in ...

More than 80% of oncologists participating in a global survey consider insurance a major barrier to timely cancer care.

AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen ...